[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cellular-proto-oncogene-bcl1":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Cellular proto-oncogene BCL1",7,6,[8,16,23,29,36,42,48],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05976763","Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma",[12],"Phase 3","RECRUITING","2026-08-26T02:17:07.954622Z","2026-07-19T19:36:05.124289Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06675123","Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma",[20],"Phase 1","2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.583743Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06084936","A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed\u002FRefractory Mantle Cell Lymphoma",[12],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.290108Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05910801","Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[33],"Phase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.931684Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[33],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[33],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":49,"title":50,"phases":51,"status":53,"updated_at":54,"content_modified":55},"NCT04092673","Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies",[52],"Phase 1\u002FPhase 2","UNKNOWN","2026-08-03T03:49:37.452409Z","2026-05-05T02:43:28.655464Z"]